All In Biotech

Drug Trial Radar · NCT03747653

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Last checked: Nov 19, 2026Latest source record: May 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Mar 8, 2019

Primary completion

May 31, 2020

Study completion May 31, 2020

Sponsor

Sponsor type
Industry
Collaborators
Beijing Furen Biomedical Research Institute Co., Ltd.
First posted
Nov 20, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A. Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in patients with hemophilia A.

Conditions

  • Hemophilia A

Interventions

  • ADVATEDrug

    Patients will be administered a single dose of ADVATE.

  • FRSW107Drug

    Patients will be administered a single dose of FRSW107 for Injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum measured concentration of FVIII:C (Cmax).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
  2. Time required for the concentration of the drug to reach half of its original value (T1/2).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
  3. Area Under the Curve to Infinity (AUC).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
  4. The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Hematology Department, Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Southern Medical University Nanfang Hospital

    Guangzhou, Guangzhou, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.